Cryopreserved HepaRG™ Cells: An Alternative In Vitro Screening Tool for Drug-Drug Interaction and Safety Applications



Important Note: No sessions of this seminar are currently scheduled. If you are interested in attending future sessions of this seminar, please contact Breanne Custodio at breanne.custodio@lifetech.com

Primary hepatocyte model systems remain the “gold standard” for in vitro studies to assess human metabolism and induction of metabolism. However, the use of primary human hepatocytes (PHH) in screening applications is limited by hepatocyte availability, donor variability, high costs, and a relative short lifespan (=10 days) in culture using standard methodologies (i.e. sandwich cultures). The use of HepaRG™ Cells in hepatic screening applications may solve these limitations without sacrificing critical mature hepatocyte phenotypes such as drug metabolizing enzymes, transport proteins, and functional xenobiotic sensing pathways (CAR, PXR, AhR).

During this webinar, we will demonstrate the utility and reproducibility of differentiated, cryopreserved HepaRG™ Cells in hepatic screening applications. We will show data which demonstrate that cryopreserved HepaRG™ Cells are metabolically competent and maintain functional xenobiotic sensing pathways similar to those exhibited in PHH cultures. Finally, we will show the utility of cryopreserved HepaRG™ Cells in the evaluation of intrinsic and metabolically-activated toxicity.

About the Presenters
Dr. Jonathan P. Jackson, Research Scientist, Life Technologies,

Dr. Jackson is currently an R&D Staff Scientist within the Discovery and ADME/Tox Systems Business Unit of Life Technologies. He joined Life Technologies in 2007 to manage, design, and implement contracted in vitro drug metabolism studies including cytochrome P450 induction studies, cytochrome P450 inhibition studies, cytochrome P450 reaction phenotyping studies, and drug clearance studies. Dr. Jackson received his Doctorate in Molecular and Cellular Toxicology from North Carolina State University in a graduate partnership program with the National Institute of Environmental Health Sciences (NIEHS). His pre-doctoral research was conducted at the NIEHS within the Human Metabolism Section of the Laboratory of Pharmacology and Chemistry under the direction of Drs. Joyce Goldstein and Masahiko Negishi.

Dr. Jackson’s dissertation examined the role of nuclear receptors in the drug-induced transcriptional activation of cytochrome P450 enzymes, especially the CYP2Cs.

Before joining Life Technologies, Dr. Jackson completed a post-doctoral research fellowship at the University of Arizona under the tutelage of Dr. Nathan Cherrington. Cherrington’s laboratory was focused on disease-drug interactions and examined the effects of nonalcoholic fatty liver disease (NAFLD) on drug metabolism and disposition.


Webinars by MeetingBridge